Inhibition of Complement C3 in GA with NGM621: Phase 1 Study Results

Related

• 

  Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy

  Roger A. Goldberg, MD, MBA

  Annual Meeting Talks

  2023

• 

  Expert Panel: Sustainability

  Geoffrey G. Emerson, MD, PhD, FASRS

  Jacob D. Grodsky, MD

  David R Anderson, MD, PharmD

  Scott M McClintic, MD

  Annual Meeting Talks

  2024

• 

  Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

  Jared S. Nielsen, MD, MBA

  Updates from the Field

  2022